Payment overview · 2025
General Payments
$140.31
9 reported records · 7 companies
Healthcare provider profile · identity verified
Scott Allen Lawrence, MD
Allopathic & Osteopathic Physicians|Family Medicine · DETROIT LAKES, MN · NPI 1407874076
Verified facts
What the public records show
CMS Open Payments records show Scott Allen Lawrence, MD received $140.31 in general payments during 2025 across 9 reported records.
AstraZeneca Pharmaceuticals LP accounted for 24.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $34.57 | 24.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $28.93 | 20.6% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.73 | 14.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.64 | 14.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.76 | 9.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.50 | 9.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $9.18 | 6.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $140.31 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $28.93 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.73 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $19.64 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.50 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.50 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $9.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
84 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 413 | 108 |
| Lisinopril | Lisinopril | 359 | 95 |
| Hydrochlorothiazide | Hydrochlorothiazide | 238 | 65 |
| Omeprazole | Omeprazole | 211 | 54 |
| Levothyroxine Sodium | Levothyroxine Sodium | 203 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 189 | 58 |
| Amlodipine Besylate | Amlodipine Besylate | 156 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 152 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 138 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 128 | 43 |
| Gabapentin | Gabapentin | 121 | 33 |
| Simvastatin | Simvastatin | 119 | 31 |
| Prednisone | Prednisone | 116 | 66 |
| Trazodone Hcl | Trazodone Hcl | 112 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 108 | 31 |
| Metformin Hcl | Metformin Hcl | 107 | 31 |
| Furosemide | Furosemide | 100 | 33 |
| Losartan Potassium | Losartan Potassium | 100 | 35 |
| Montelukast Sodium | Montelukast Sodium | 93 | 24 |
| Tramadol Hcl | Tramadol Hcl | 86 | 24 |
| Potassium Chloride | Potassium Chloride | 85 | 26 |
| Ozempic | Semaglutide | 84 | 14 |
| Repaglinide | Repaglinide | 83 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 81 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 72 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 70 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 67 | 18 |
| Clonazepam | Clonazepam | 66 | suppressed |
| Eliquis | Apixaban | 66 | 16 |
| Famotidine | Famotidine | 65 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 63 | 17 |
| Sertraline Hcl | Sertraline Hcl | 55 | 15 |
| Azithromycin | Azithromycin | 54 | 44 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 52 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 50 | 12 |
| Finasteride | Finasteride | 49 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 43 | 15 |
| Alprazolam | Alprazolam | 42 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 42 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 42 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 42 | suppressed |
| Baclofen | Baclofen | 41 | suppressed |
| Carvedilol | Carvedilol | 39 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 38 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Atenolol | Atenolol | 37 | 12 |
| Ezetimibe | Ezetimibe | 37 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 36 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 35 | 22 |
| Propranolol Hcl | Propranolol Hcl | 33 | 12 |
| Repatha Sureclick | Evolocumab | 33 | suppressed |
| Allopurinol | Allopurinol | 32 | suppressed |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Cephalexin | Cephalexin | 32 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 21 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 27 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Risperidone | Risperidone | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Jardiance | Empagliflozin | 18 | suppressed |
| Meloxicam | Meloxicam | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Itraconazole | Itraconazole | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $140.31 · 9 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Kerendia, MOUNJARO, REXULTI, The Cologuard Plus Collection Kit, VOQUEZNA, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error